Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

350.30
+5.551.61%
Post-market: 350.300.00000.00%17:06 EDT
Volume:380.51K
Turnover:131.24M
Market Cap:9.76B
PE:-27.23
High:351.72
Open:343.00
Low:333.46
Close:344.75
52wk High:392.70
52wk Low:37.19
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.22
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:7.28
PE(LYR):-25.99

Loading ...

Guggenheim Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

S&P 500 Futures Fall In Premarket Trading; Hewlett Packard Ent, Marvell Technology Lead

Dow Jones
·
Jun 02

Wells Fargo Sticks to Its Hold Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

Buy Rating Reaffirmed as Higher Relutrigine Pricing Assumptions Offset Vormatrigine Setback; $537 Price Target Maintained

TIPRANKS
·
Jun 02

Yazdi Maintains Buy on Praxis, Trims Price Target to $810 as Vormatrigine Outlook Softens but Core Pipeline Thesis Remains Intact

TIPRANKS
·
Jun 02

Praxis Precision Medicines Inc : TD Cowen Cuts Target Price to $510 From $554

THOMSON REUTERS
·
Jun 02

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

TIPRANKS
·
Jun 02

Praxis Precision Medicines, Inc. : H.c. Wainwright Cuts Target Price to $1201 From $1245

THOMSON REUTERS
·
Jun 02

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Praxis Precision Medicines Inc : Baird Cuts Target Price to $400 From $433

THOMSON REUTERS
·
Jun 02

Praxis Precision Reassesses Vormatrigine After Mixed POWER1 Data

TIPRANKS
·
Jun 02

Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint

Dow Jones
·
Jun 02

Praxis Precision reports POWER1 study misses endpoint, pauses POWER2 enrollment

TIPRANKS
·
Jun 02

Praxis says POWER1 trial of vormatrigine in focal seizures misses primary endpoint

Reuters
·
Jun 02

Praxis Precision Medicines - Power1 Study Did Not Meet Primary Endpoint in Refractory Focal Onset Seizures

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines - Pauses Enrollment in Power2 Study to Reassess Vormatrigine Program

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines - Secondary 50% Response Rate Met; Seizure Reduction More Pronounced at 30 Mg Dose

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines Provides Vormatrigine Program Update

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines - Vormatrigine Well-Tolerated With Adverse Event Discontinuations Below 10%

THOMSON REUTERS
·
Jun 02